JP5572451B2 - Anti-ofloxacin monoclonal antibody and immunoassay for ofloxacin using the same - Google Patents

Description

The present invention relates to an antibody that reacts with ofloxacin, which is an antibacterial compound, and / or each optically active substance constituting the antibacterial compound, and does not react with these major metabolites.

New quinolone antibacterial agents are drugs in which the antibacterial spectrum and antibacterial activity of pyridone carboxylic acid antibacterial agents such as enoxacin and norfloxacin are drastically enhanced, and exhibit high selective toxicity by inhibiting bacterial DNA gyrase. So far, ofloxacin, levofloxacin, norfloxacin, ciprofloxacin and the like have been used clinically for the purpose of treatment of various infectious diseases and purulent diseases, and have shown excellent therapeutic effects.

Ofloxacin has the following chemical formula (I)
Which has one asymmetric carbon in its chemical structure and contains two kinds of optically active S-(-) and R-(+) isomers at a composition ratio of 1: 1. Is the body. Among the racemates, the antibacterial activity main body is levofloxacin which is an S-(−) isomer. Levofloxacin is known to exhibit antibacterial activity almost twice that of ofloxacin, and is highly effective in various infectious diseases including respiratory infections and urinary tract infections.

In order for the antibacterial agent to exert its effect sufficiently, it is important that an appropriate amount of the active ingredient is present in the body. Therefore, only compounds with antibacterial activity that exist in the body without measuring compounds such as metabolites that have diminished or lost antibacterial activity (hereinafter sometimes referred to as “compounds that have lost antibacterial activity”). A measurement system that quantifies the amount of water is indispensable for the most effective formulation of antibacterial agents. Methods for measuring only compounds with antibacterial activity include immunoassay methods using antibodies that specifically recognize the test antibacterial agent, methods for separation and analysis by HPLC based on the molecular weight and polarity of the test antibacterial agent, A method of directly measuring antibacterial activity by culturing is widely used. Among these, the immunoassay method is advantageous because it does not require the use of an expensive instrument, can be measured in a short time, has excellent sensitivity, and can cope with the measurement of a large number of samples.

In addition, when administered by various routes, many drugs reversibly bind to biological components such as serum proteins such as albumin, glycoproteins, and lipoproteins (hereinafter sometimes collectively referred to as serum proteins). It is known to do. In other words, the concentration of the drug present in the blood corresponds to the sum of the concentration of bound drug bound to serum proteins and the concentration of free (unbound) drug not bound to serum proteins. In order to accurately measure drugs in blood by immunoassay methods using antibodies, it is necessary that the antibody used reacts equally to both bound and free drugs, but serum proteins bound to the drugs May interfere with the antibody binding to the antigenic determinant of the drug, making it impossible to accurately measure the drug concentration in the blood.

As an immunoassay method for detecting a new quinolone antibacterial agent, an immunoassay method using a monoclonal antibody that recognizes a bicyclic new quinolone antibacterial agent but does not recognize a tricyclic new quinolone such as ofloxacin has been published. (Patent Document 1). However, the object of the present invention is to detect the residual amount of bicyclic new quinolone used for the prevention of infectious diseases of livestock and cultured fish and shellfish and cannot detect ofloxacin. The present invention is also aimed at obtaining an antibody capable of simultaneously detecting many types of new quinolone antibacterial agents (in other words, an antibody that cross-reacts with many types of new quinolone antibacterial agents).

On the other hand, Patent Document 2 discloses an antibody and an immunological measurement method for levofloxacin, which is the S form of the compound represented by formula (I). The antibody is a polyclonal antibody that is also cross-reactive with metabolites that have lost antibacterial activity (levofloxacin-N-oxide, desmethyllevofloxacin). Therefore, there was a problem that only levofloxacin that did not lose antibacterial activity could not be detected accurately.

JP 2007-63180 A JP-A-7-267999

The antigenicity of new quinolone antibacterial compounds, including ofloxacin, is extremely low,
Even if these compounds themselves are directly used for immunization as an antigen (immune antigen) used for producing an antibody, it is difficult to efficiently produce an antibody that recognizes a new quinolone antibacterial compound. Therefore, it is appropriate to use an antigen for producing an antibody that recognizes a new quinolone antibacterial compound, in which a protein (carrier protein) as a carrier is bound to these compounds. Conventionally, the binding of a new quinolone antibacterial compound and a carrier protein has a functional group that affects antigenicity, such as quinolone skeleton 4
It has been considered necessary to bind a new quinolone antibacterial compound and a protein without damaging the ketone (carbonyl) group at the position, the carboxy group at the 3 position, or the fluorine atom. Therefore, in Patent Document 2, 4 which is the 10-position substituent of levofloxacin
A compound obtained by converting a -methyl-piperazinyl group into a 4-carboxymethylpiperazinyl group is combined with bovine serum albumin (BSA) as a carrier and used as an antigen for immunization.

However, the antibody obtained by the method of Patent Document 2 is a levofloxacin metabolite (N-
Oxide, demethylated) also show a cross-reaction, and an antibody that reacts only with levofloxacin has not been obtained.

An object of the present invention is to provide an antibody that recognizes the compound represented by formula (I) and does not recognize N-oxide and demethylated metabolites (does not cross-react) and a method for producing the same. Yes. Another object of the present invention is to provide immunoassay methods using these antibodies, for example, radioimmunoassay methods, enzyme immunoassay methods, carrier (particle) aggregation inhibition immunoassay methods, and immunochromatography methods. A further object of the present invention is to provide an antigen for immunization useful for the production of the antibody.

The present inventor made levofloxacin [(−)-(S) -9-fluoro-2,3-dihydrr
o-3-methyl-10- (4-methyl-1-piperazinyl) -7-oxo-
7H-pyrido [1,2,3-de] [1,4] benzoxazine-6-carb
The present inventors succeeded in producing an excellent antigen for immunization that can achieve the above-mentioned object by binding a carrier protein such as bovine serum albumin to a carboxy group that is the 6-position substituent of oxylicacid].
In addition, by using the immunizing antigen, it is possible to provide a useful antibody that reacts with the compound represented by the formula (I) and does not recognize N-oxide and demethylated metabolites thereof. I found. Further, by using the immunizing antigen, the compound of formula (I)
It was found that a useful antibody that recognizes levofloxacin, which is an S form of the compound represented by the formula (II), and does not recognize its metabolites, levofloxacin N-oxide and levofloxacin demethylated form, can be provided. Furthermore, by using the immunizing antigen, a useful antibody that recognizes the R form of the compound represented by the formula (I) and does not recognize the metabolite N-oxide form and demethylated form is provided. I found what I could do. In addition, an immunoassay method for measuring a compound represented by the formula (I) that is not metabolized or decomposed using the antibody was completed. The present invention has been completed based on the above findings.

Therefore, the present invention provides an antibody that reacts with the compound represented by the formula (I) and does not recognize N-oxide and demethylated metabolites thereof. According to one embodiment of the present invention, there is provided an immunizing antigen that is a conjugate of levofloxacin, which is the S form of the compound represented by formula (I), and a carrier protein. According to one embodiment of the present invention, there is provided an immunizing antigen in which a carrier protein is bound to a carboxy group that is a 6-position substituent of levofloxacin. Further, by immunizing an animal using these antigens, R-form and S-form of the compound represented by formula (I),
Or only levofloxacin, which is the S form of the compound represented by formula (I), or formula (I)
And a method for producing an antibody that recognizes only the R-form of the compound represented by the formula and does not recognize N-oxide and demethylated metabolites thereof, and an antibody produced by the method. . Furthermore, the present invention provides a method for measuring the concentration of a compound represented by formula (I) in a sample by an immunoassay method using these antibodies.
That is, the present invention has the following configuration.
(1) An antibody that reacts with a compound represented by the following formula (I) and does not cross-react with an N-oxide and / or demethylated metabolite thereof.
(2) The antibody according to (1) above, which is an antibody that reacts strongly with the S form of the compound represented by formula (I).
(3) The antibody according to (1) above, which is an antibody that reacts strongly with the R form of the compound represented by formula (I).
(4) The antibody according to (1) above, which is an antibody that reacts strongly with a racemate of the compound represented by formula (I).
(5) Diclofenac sodium, nabumetone, flurbiprofen, ketoprofen,
In the above (1), it does not cross-react with any one or more selected from the group consisting of loxoprofen sodium, oxaprozin, naproxen, ibuprofen, carbocysteine, salicylamide, acetaminophen, anhydrous caffeine, methylene disalicylic acid, promethazine and theophylline. The antibody described.
(6) The antibody according to (1), which does not cross-react with a new quinolone antibacterial agent excluding the compound represented by the formula (I) or has low cross-reactivity.
(7) The antibody according to any one of (1) to (6), wherein the reactivity with the compound represented by the formula (I) is not changed by the coexistence of a component derived from a biological sample.
(8) The antibody according to any one of (1) to (7), wherein the biological sample-derived component is a serum component, a plasma component, or a saliva component.
(9) The reactivity with the compound represented by the formula (I) is not changed by the binding of the compound represented by the formula (I) and a serum component, according to any one of (1) to (6) above antibody.
(10) The antibody according to any one of (1) to (9) above, which is a monoclonal antibody.
(11) A monoclonal antibody specific for the compound represented by formula (I), the compound in the sample and the sample so that an immune reaction between the antibody immobilized on the solid phase and the antibody is inhibited In the reaction system in which the N-oxide and / or demethylated form of the compound is present,
The 50% inhibitory activity of the immune response by the compound in the sample is determined by the N-
The monoclonal antibody according to (10), which satisfies a reaction condition that is greater than the 50% inhibitory activity of the immune reaction caused by an oxide and / or a demethylated form.
(12) A hybridoma that produces the monoclonal antibody according to (10) or (11).
(13) An antigen for producing the antibody according to (1), which is bound to a carrier protein via a carboxy group at position 6 of the compound represented by formula (I).
(14) The antigen according to (13), wherein the carrier protein is BSA or transferrin.
(15) The antigen according to (13) or (14) above, wherein 12 to 14 molecules of the compound represented by the formula (I) are bound per molecule of carrier protein.
(16) An immunization method comprising immunizing an animal with the antigen according to any one of (13) to (15).
(17) A formula in which an antibody obtained by immunizing an animal with the antigen according to any one of (13) to (15) is immobilized on a solid phase in the presence of a compound whose cross-reactivity is to be confirmed A method for screening an antibody, wherein a desired antibody is selected by reacting with the compound represented by (I) and comparing with the reactivity in the absence of the compound whose cross-reactivity is to be confirmed.
(18) Formula (I) in which an antibody obtained by immunizing an animal with the antigen according to any one of (13) to (15) above is immobilized on a solid phase in the presence of a biological sample-derived component A method for screening an antibody, wherein a desired antibody is selected by reacting with the indicated compound and comparing with reactivity in the absence of a biological sample-derived component.
(19) A method for immunological measurement of a compound represented by formula (I) in a sample, wherein the antibody according to any one of (1) to (11) is used.
(20) For the antibody according to any one of (1) to (11) above immobilized on a solid phase,
A method for immunological measurement of a compound represented by formula (I) in a sample, comprising competitively reacting a synthetic multivalent antigen and the compound represented by formula (I) in the sample.
(21) The antibody according to any one of (1) to (11) above, wherein the immobilized polyvalent antigen and the compound represented by formula (I) in the sample are competitively reacted. An immunological measurement method for a compound represented by formula (I) in a sample.
(22) The antibody according to any one of (1) to (11) above, immobilized on a solid phase,
A method for immunological measurement of a compound represented by formula (I) in a sample, characterized by competitively reacting a solid-phased synthetic multivalent antigen and the compound represented by formula (I) in the sample.
(23) The immunological measurement method according to any one of (19) to (22), wherein the solid phase is latex particles.
(24) The immunological measurement method according to any one of (19) to (23), wherein the competitive reaction is measured by an aggregation inhibition method.
(25) The immunological measurement according to any one of (19) to (24), wherein the sample is biological blood, serum, plasma, urine, saliva, sputum, tears, ear leakage or prostate fluid. Method.
(26) The above (25), wherein the sample is a sample of a patient administered with the compound represented by formula (I)
An immunological measurement method according to 1.
(27) A reagent for immunological measurement of a compound represented by formula (I) in a sample, characterized by comprising the following (a) and (b):
(A) Immobilized on the antibody or solid phase according to any one of (1) to (11) above (1)
To (11) (b) a synthetic multivalent antigen or a solid-phased synthetic multivalent antigen

The antibody provided by the present invention is a useful antibody that recognizes the compound represented by the formula (I), and is represented by the formula (I) in various samples, for example, biological samples, by an immunoassay method using the antibody. The concentration of the compound can be measured with high sensitivity.

FIG. 1 shows the results of measuring antibody titers in mouse antisera by antigen-immobilized ELISA. FIG. 2 shows the results of measurement of the relationship between the amount of free levofloxacin added and the reaction amount (Abs.) Of the antibody in the mouse antiserum to the immobilized antigen by the competitive ELISA method. FIG. 3 shows the results of measurement of the relationship (crossover rate) between the amount of free levofloxacin added and the reactivity of each monoclonal antibody to the immobilized antigen by the competitive ELISA method. FIG. 4 shows a calibration curve by a competitive ELISA method using a standard product. FIG. 5 shows the results of a dilution linearity test at each serum addition concentration. FIG. 6 shows the correlation between the measured value and the theoretical value by the competitive ELISA method using a sample with a known concentration. FIG. 7 shows the results of examining the effect of saliva addition on the competitive ELISA assay system. FIG. 8 shows the results of examining the influence of plasma addition on the competitive ELISA assay system. FIG. 9 shows the results of examining the effect of plasma addition on a competitive ELISA assay system using conventional antibodies. FIG. 10 shows a calibration curve by a one-step competitive ELISA method using a standard product. FIG. 11 shows a calibration curve obtained by the latex agglutination inhibition method (antibody-immobilized latex system) using a standard product. FIG. 12 shows the correlation between measured values and theoretical values by the latex aggregation inhibition method (antibody-immobilized latex system) using levofloxacin-containing human serum of known concentration. FIG. 13 shows the correlation between measured values and theoretical values by the latex aggregation inhibition method (antibody-immobilized latex system) using levofloxacin-containing human plasma having a known concentration. FIG. 14 shows the correlation between the concentration of levofloxacin in saliva containing levofloxacin of known concentration and the change in absorbance measured by the latex aggregation inhibition method (antibody-immobilized latex system). FIG. 15 shows a calibration curve obtained by a latex agglutination inhibition method (antigen-immobilized latex system) using a standard product. FIG. 16 shows the correlation between the amount of levofloxacin used as a raw material and the binding ratio to BSA when a synthetic multivalent antigen was prepared using BSA as a carrier. FIG. 17 shows the ratio of levofloxacin binding to BSA and the amount of levofloxacin in the sample measured by the latex aggregation inhibition method (antibody-immobilized latex system) at 0.0 μg / mL and 16.0 μg / mL. The correlation of a difference in absorbance is shown.

The antibody of the present invention needs to be an antibody that reacts with the compound represented by the formula (I) and does not cross-react with its metabolite, N-oxide and / or demethylated form. Since it reacts with the compound represented by the formula (I) and does not react with its metabolite, the compound represented by the formula (I) which is effectively present as an antibacterial agent in the blood when the antibody of the present invention is used in an immunoassay. Can be measured specifically, and is very useful.
Another embodiment of the antibody of the present invention is an antibody that reacts strongly with levofloxacin, which is the S form of the compound represented by formula (I), or an antibody that reacts strongly with the R form of the compound represented by formula (I),
It is an antibody that reacts with both R and S isomers.
Furthermore, another embodiment of the antibody of the present invention is not reactive or reactive with a new quinolone antibacterial agent which is a concomitant drug of the compound represented by formula (I) or a similar compound of the compound represented by formula (I). It is a weak antibody.
The antibody of the present invention may be a polyclonal antibody obtained from the serum (antiserum) of an immunized animal, or a monoclonal antibody produced from a hybridoma prepared using antibody-producing cells of the immunized animal.
The meanings of the terms “cross-react”, “strongly react”, “do not react”, and “low reactivity” will be described later.

In accordance with the present invention, as an antigen (antigen for immunization) used for producing an antibody that recognizes the S-form and / or R-form of the compound represented by the formula (I), the compound represented by the formula (I) is recognized, Any antigen may be used as long as it produces an antibody that does not recognize N-oxide and demethylated metabolites thereof. Among them, carboxy which is the 6-position substituent of the compound represented by formula (I) It is appropriate to use an antigen produced by binding a carrier such as a protein (hereinafter sometimes referred to as “carrier”) to a group.

A protein used as a carrier of an antigen for immunization (“carrier protein”) may be appropriately selected from various proteins that are generally useful for antibody production against a low molecular antigen (hapten). Binding to an antigen can be performed by a method known per se. For example, bovine serum albumin or transferrin can be used as a carrier protein, and a condensing reaction using dicyclohexylcarbodiimide or an active ester method can be used for binding the carrier protein to an antigen. The type and the method of binding the carrier protein and the antigen are not limited to these specific examples.

Further, the number of molecules of the compound represented by the formula (I) bound per molecule of carrier protein (the number of bonds) may be any number as long as it can be recognized as an antigen in the immunized animal. Considering the efficiency of antibody production, for example, 12-14 per carrier protein molecule
Although an antigen to which a compound represented by the formula (I) of the molecule is bound is desirably used, the number of binding is not limited to this range. Details of the method for preparing the antigen for immunization will be described later. By increasing or decreasing the amount of the compound represented by the formula (I) used as a raw material for the reaction in the reaction at the time of preparation with respect to the carrier protein, a desired number of the formula (I) It is possible to bind a compound represented by That is, if the amount of the compound added as a raw material is increased, the number of bonds increases, and if the amount of the compound added as a raw material is decreased, the number of bonds decreases. In the present specification, “binding ratio” and “binding amount” may be expressed in the same meaning as “number of bonds”.

In addition, the antigen for immunization of the present invention prepared by the above method can be used as an antigen for screening a hybridoma or antibody, and further as an antigen for an immunological measurement method described later (antigen for competitive reaction). . When used as an antigen for screening or an immunoassay, it can be used by immobilizing (immobilizing) it on a solid (solid phase) such as an insoluble carrier, or it can be commonly used by those skilled in the art described later. It can be used as a labeled antigen labeled with any labeling substance. Any of such immobilized (solid phase) antigen and labeled antigen is included in the scope of the present invention. For example, an immobilized (solid phase) antigen can be produced by physically adsorbing or chemically binding the antigen to an insoluble carrier. In the case of chemical bonding, an appropriate spacer may be interposed.

As the insoluble carrier, an insoluble carrier comprising a polymer substrate such as polystyrene resin, an inorganic substrate such as glass, a polysaccharide substrate such as cellulose or agarose, and the shape thereof is not particularly limited, As a solid phase when immobilizing as an antigen for screening that can be selected in any shape such as plate (for example, microplate or membrane), beads or particles (for example, latex particles), cylinder (for example, test tube) As a solid phase in the case of immobilizing as a microplate or an antigen for an immunological measurement method, a microplate or a latex particle can be mentioned as a suitable example.

The antibody of the present invention dissolves the antigen described above in a solvent such as phosphate buffered saline (PBS),
This solution can be easily produced by immunizing an animal by administering it. If necessary, an appropriate adjuvant may be added to the solution, and then immunization may be performed using an emulsion. Adjuvants include water-in-oil emulsions, water-in-oil-in-water emulsions, oil-in-water emulsions, liposomes, aluminum hydroxide gels, and other commonly used adjuvants, as well as protein and peptide substances derived from biological components. Also good. For example, Freund's incomplete adjuvant or Freund's complete adjuvant can be preferably used. The route of administration of the adjuvant,
The dose and administration timing are not particularly limited, but it is desirable to select appropriately so that a desired immune response can be enhanced in an animal immunized with an antigen.

The type of animal used for immunization is not particularly limited, but mammals are preferable, for example, mice,
Rats, cows, rabbits, goats, sheep and the like can be used, and mice can be used more preferably. Animal immunization may be performed according to methods available in the art, for example, by injecting a solution of an antigen, preferably a mixture with an adjuvant, into the animal subcutaneously, intradermally, intravenously, or intraperitoneally. Can do. Since the immune response generally varies depending on the type and strain of the animal to be immunized, it is desirable to set the immunization schedule as appropriate according to the animal used. The antigen administration is preferably repeated several times after the first immunization.

When obtaining a polyclonal antibody, the antibody of the present invention can be obtained from the serum (antiserum) of the immunized animal, but the method is not particularly limited, and any method available to those skilled in the art can be used. A method may be used. Purification of the antibody can be performed by appropriately combining, for example, DEAE anion exchange chromatography, affinity chromatography using protein A, ammonium sulfate fractionation method, PEG fractionation method, ethanol fractionation method and the like. Whether the obtained antibody is the antibody of the present invention, that is, the target compound represented by the formula (I) is recognized, and other quinolone antibacterial agents or levofloxacin concomitant drugs (for example,
Antibiotics, anti-inflammatory analgesics, general cold medicine, airway mucosa preparation / mucosal normalizing agent, bronchodilator, etc.)
It is possible for those skilled in the art to easily confirm that an antibody has low reactivity with respect to or is an antibody that does not substantially recognize them using a well-known method. In the examples of the present specification, an animal immunization method, an antibody purification method, and an antibody property confirmation method are specifically described for the antibody production method of the present invention. The antibody of the present invention can be easily produced by adding appropriate modifications or alterations to these methods as necessary while referring to the specific explanations and specific methods of the examples.

Examples of new quinolone antibacterial agents other than the compound represented by the formula (I) include compounds similar to the compound represented by the formula (I), specifically, ciprofloxacin, tosufloxacin,
Examples include gatifloxacin, sparfloxacin, fleroxacin, lomefloxacin, enoxacin, moxifloxacin, pazufloxacin and the like.
As a concomitant drug of the compound represented by formula (I), diclofenac sodium, nabumetone, flurbiprofen, ketoprofen, loxoprofen sodium, oxaprozin, naproxen, ibuprofen, carbocysteine, salicylamide, acetaminophen, anhydrous caffeine, methylene Examples include disalicylic acid, promethazine, and theophylline.
As one aspect of the antibody of the present invention, it does not cross-react with any one or more of these compounds,
An antibody with weak cross-reactivity may be mentioned. When this antibody is used for measurement of a compound represented by the formula (I), the compound represented by the formula (I) It can be measured specifically.

In order to obtain a monoclonal antibody, the following operation is subsequently performed, but the present invention is not limited thereto. The production method of the monoclonal antibody itself is well known in the art,
Since it is widely used, those skilled in the art can easily produce the antibody of the present invention by using the antigen (for example, Antibodies, A Laboratory).
Manual (Cold Spring Harbor Laboratory Pre
ss, (1988) See Chapter 6).

After the final immunization, spleen cells or lymph node cells, which are antibody-producing cells, are removed from the immunized animal, and hybridomas can be prepared by cell fusion with a cell line derived from myeloma having high proliferation ability. For cell fusion, cells having high antibody production ability (quality / quantity) are preferably used, and cell lines derived from myeloma are preferably compatible with animals from which antibody-producing cells to be fused are derived. Cell fusion can be performed according to a method known in the art. For example, a polyethylene glycol method, a method using Sendai virus, a method using an electric current, or the like can be employed. The obtained hybridoma can be grown according to conditions generally used in the art, and a desired hybridoma can be selected while confirming the properties of the antibody produced. The hybridoma can be cloned by a known method such as a limiting dilution method or a soft agar method.
Hybridoma selection can be performed efficiently at the selection stage in consideration of the conditions under which the produced antibody is used for actual measurement. For example, an antibody obtained by immunizing an animal is reacted with a compound represented by formula (I) immobilized on a solid phase in the presence of a compound whose cross-reactivity is to be confirmed, and the cross-reactivity is confirmed. By comparing with reactivity in the absence, hybridomas producing the desired antibody can be selected more efficiently. In addition, an antibody obtained by immunizing an animal is reacted with a compound represented by the formula (I) immobilized on a solid phase in the presence of a biological sample-derived component, and a reaction in the absence of the biological sample-derived component The hybridoma producing the desired antibody can also be selected more efficiently by comparing with the sex.

After the cloning step, the binding ability of the antibody produced and the compound represented by formula (I) is determined by ELISA.
By assaying using a method such as the A method, the RIA method, or the fluorescent antibody method, it can be confirmed whether or not the selected hybridoma produces a monoclonal antibody having a desired property. Here, in order to efficiently obtain an antibody that recognizes the compound represented by the formula (I) and does not recognize its metabolite, the compound represented by the formula (I) is bound to a protein as an antigen used for screening a hybridoma. It is preferable to use a protein that is different from the protein of the immunizing antigen.
Monoclonal antibodies having desired characteristics can be produced by mass-culturing the hybridomas selected as described above. The mass culture method is not particularly limited. For example, the hybridoma is cultured in an appropriate medium and a monoclonal antibody is produced in the medium, or the hybridoma is injected into the abdominal cavity of a mammal to be proliferated, and then in ascites. Examples thereof include a method for producing an antibody. Purification of the monoclonal antibody should be carried out by appropriately combining the above-described antibody purification methods from antiserum, such as DEAE anion exchange chromatography, affinity chromatography, ammonium sulfate fractionation method, PEG fractionation method, and ethanol fractionation method. Can do.

As the antibody of the present invention, in addition to the whole antibody molecule, it is also possible to use an antibody fragment having antigen-antibody reaction activity. In addition to those obtained through the immunization process for animals as described above, It is also possible to use those obtained by using techniques or chimeric antibodies. The antibody fragment is preferably a functional fragment, for example, F (ab ′) ₂
, Fab ′ and the like. These fragments can be produced by treating the antibody obtained as described above with a proteolytic enzyme (for example, pepsin or papain).

In addition, the monoclonal antibody of the present invention can be used as an immobilized (solid phase) antibody immobilized on an insoluble carrier, or a labeled antibody labeled with a commonly used labeling substance known to those skilled in the art described later. Any of such immobilized antibodies and labeled antibodies are included in the scope of the present invention. For example, an immobilized antibody can be produced by physically adsorbing a monoclonal antibody to an insoluble carrier or chemically binding it (may be via an appropriate spacer). As an insoluble carrier, a polymer substrate such as polystyrene resin, an inorganic substrate such as glass,
An insoluble carrier comprising a polysaccharide base material such as cellulose or agarose can be used,
The shape is not particularly limited, and any shape such as a plate shape (for example, a microplate or a membrane), a bead or particle shape (for example, latex particles), or a tubular shape (for example, a test tube) can be selected.

By using a labeled antibody (secondary antibody) that can bind to the antibody of the present invention, the amount of the antibody of the present invention bound to the compound represented by formula (I) can be measured, whereby the formula in the sample can be measured. (
The compound represented by I) can be detected. Examples of labeling substances for producing labeled antibodies include enzymes, fluorescent substances, chemiluminescent substances, biotin, avidin, or radioisotopes,
Examples thereof include colloidal gold particles and colored latex. As a method for binding a labeling substance and an antibody, a glutaraldehyde method, a maleimide method, a pyridyl disulfide method available to those skilled in the art,
Alternatively, a method such as the periodic acid method can be used, but the types of the immobilized antibody and the labeled antibody and the production method thereof are not limited to the above examples. For example, when an enzyme such as horseradish peroxidase (HRP) or alkaline phosphatase (ALP) is used as a labeling substance, a specific substrate of the enzyme (when the enzyme is HRP, for example, O-phenylenediamine (OPD) or 3,3 ′, 5,5′-tetramethylbenzidine (TMB
In the case of ALP, enzyme activity can be measured using p-nitrophenyl phosphate, etc.), and when biotin is used as a labeling substance, it is common to react at least with avidin or enzyme-modified avidin. is there.

Using the antibody of the present invention, for example, a compound represented by the formula (I) present in a sample can be detected. In the present specification, when the term “compound represented by formula (I)” is simply referred to, S-form, R-form, and S-form and R-form, which are two types of optically active forms of the compound represented by formula (I): 1
It is used in the concept including any racemic mixture. Therefore, “an antibody that reacts with the compound represented by the formula (I)” means an antibody that reacts with the R form of the compound represented by the formula (I), the formula (I
An antibody that reacts with the S form of the compound represented by formula (I), and the S form and R of the compound represented by the formula (I)
It will be used in a concept that includes antibodies that react to both bodies.
“Racemic” and “ofloxacin” are used synonymously, and “S-form of the compound represented by formula (I)” and “levofloxacin” are used synonymously.

In this specification, “insoluble carrier” is “solid phase”, antigen or antibody is physically or chemically supported on an insoluble carrier, or the state in which it is supported is “fixed”, “immobilized”, “solid phased” May be expressed. In addition, the term “detection” or “measurement” should be interpreted in the broadest sense including proof and / or quantification of the presence of the compound represented by formula (I), and should be interpreted in a limited manner in any sense. should not be done.

Examples of the “sample” to be detected in the measurement method using the antibody of the present invention include body fluids derived from living organisms (organisms), specifically blood, serum, plasma, urine, saliva, sputum, tears. Examples include, but are not limited to, fluid, otorrhea or prostate fluid. For example,
Naturally, samples extracted from tissues of livestock and seafood, feed and water used in livestock breeding and seafood culture processes, and the like can be used as a sample of the present invention. Among these samples, the bodily fluid of a patient who has been administered ofloxacin is particularly preferably used because of its relation to treatment.
In the present specification, the “biological sample-derived component” means a component constituting the sample,
For example, serum proteins such as albumin and globulin, serum proteins such as glycoproteins and lipoproteins as serum components when the biological sample is serum, and plasma proteins (serum) as plasma components when the biological sample is plasma. (Including blood coagulation factors not included in the above) and saliva components when the biological sample is saliva, such as enzymes such as lysozyme and mucopolysaccharides. It is mentioned elsewhere in this document that these may bind to the administered ofloxacin, etc., and may interfere with the recognition of antigenic determinants by the antibody.

Further, in this specification, “lost antibacterial activity” refers to what is generally called “metabolite”, “degradation product”, or the like, in which the antibacterial compound is changed, and the unchanged compound has A part of the antibacterial spectrum or activity that has been lost or weakened. Furthermore, “bound type” means that the antigen is reversibly or irreversibly bound to the sample-derived protein in the measurement system and artificially bound to various carriers. Means that it is not bound to a sample-derived protein or various carriers.

Furthermore, in the present specification, that the antibody of the present invention “recognizes” an antigen and “
It is synonymous with “reacting” and “cross-reacting”, and further synonymous with “binding” with an antigen, but is not limited thereto and should be interpreted in the broadest sense.

“No cross-reaction” between the antibody of the present invention and a compound means that it does not react at all with a compound. Quantitatively, the cross-reactivity is 1 according to the criteria for reaction in the competitive ELISA method of Example 1. If less than%.
The term “weak cross-reactivity” between an antibody of the present invention and a compound means that the compound reacts with a certain compound but its cross-reactivity is lower than the cross-reactivity with other compounds. This refers to a case where the recognition can be sufficiently distinguished, and quantitatively refers to the case where the cross-reactivity is 1% or more and less than 40% according to the determination of cross-reactivity in the competitive ELISA method of Example 1.
“Strongly reacting with S-form” means reacting more strongly with S-form than R-form of the compound represented by formula (I), and quantitatively, ofloxacin and antibody in the competitive ELISA method of Example 1 The cross-reactivity is less than 100% according to the determination of the cross-reactivity. “Strongly reacts with R-form” refers to the case where the cross-reactivity is greater than 100% according to the same determination.
“The reactivity with the compound represented by the formula (I) does not change due to the coexistence of the biological sample component” means that the reaction between the antibody of the present invention and the free-form compound represented by the formula (I) When the reaction is performed in the presence and absence of the derived sample component and the reactivity of both is compared, it means that there is no substantial change. In the case where the reactivity changes due to coexistence, in addition to binding to a drug in pharmacokinetics, for example, a highly viscous substance such as mucopolysaccharide in saliva is an antigenic determinant in the compound represented by formula (I) And the like, which may interfere with the binding of the antibody to.
“The reactivity of the compound represented by the formula (I) does not change due to the binding of the compound represented by the formula (I) and the serum component” means that the antibody of the present invention is expressed by the formula (I) in the serum sample. Properties required for use in measuring the indicated compounds, serum components such as serum albumin and formula (I)
A state in which the reactivity between the antibody and the compound represented by formula (I) is not lost or weakened due to the binding of the compound represented by Quantitatively, in the test for examining the effect of incubating the compound represented by the formula (I) with human serum by the competitive ELISA method of Example 3, the reactivity at the incubation time of 0 minutes and at the incubation time of 15 minutes The difference is less than 5%.
Further, when measuring the reactivity between the antibody of the present invention and the free form of the compound represented by formula (I) in the competitive ELISA method, the free form of the compound represented by formula (I) is prepared using serum. Even when the difference was less than 5%, the “reactivity with the compound represented by the formula (I) is determined by the binding between the compound and the serum component”. Does not change.

Detection of the compound represented by the formula (I) in the biological sample using the antibody of the present invention can be performed by a known method (for example, the Japanese Society of Clinical Pathology, “Special Issue on Clinical Pathology Special Issue 53 Immunoassay for Clinical Examination-Technology” And Application- ”, Clinical Pathology Publications, 1983, edited by Yuji Ishikawa et al.“ Enzyme Immunoassay ”
3rd Edition, Medical School, 1987, edited by Kitagawa Tsuneki et al., “Protein Nucleic Acid Enzyme Separate Volume No. 31 Enzyme Immunoassay”, Kyoritsu Shuppan, 1987, etc.). However, the method for detecting the compound represented by the formula (I) using the antibody of the present invention is not limited to those exemplified above, and it goes without saying that those skilled in the art can appropriately select depending on the purpose. . Since specific measurement methods are shown in the examples of the present specification, a person skilled in the art can refer to the methods of the examples and add appropriate modifications or alterations to the methods as necessary to obtain biological samples. The compound represented by the formula (I) contained in can be easily and reliably detected.

As an embodiment of the measuring reagent (kit) provided by the present invention, (1) when the compound represented by formula (I) is immobilized, (2) the compound represented by formula (I) is recognized. Antibody (
When the antibody of the present invention is immobilized, (3) large when both the compound represented by formula (I) and the antibody recognizing the compound represented by formula (I) are immobilized. Can be separated.
Hereinafter, each of the examples will be described by taking ELISA as a representative labeled immunoassay method and latex agglutination inhibition method as a typical particle aggregation inhibition immunoassay method as examples. In each case, a competitive reaction with ofloxacin in the sample is used.

<Labeled immunoassay method: In particular, ELISA method as an example>

(1) When the compound represented by the formula (I) is immobilized, at least the following elements:
A measurement reagent (kit) can be constituted by (a) an insoluble carrier on which a compound represented by formula (I) is solid-phased; and (b) an antibody recognizing the compound represented by formula (I). . Here, (a) the insoluble carrier on which the compound represented by the formula (I) is solid-phased is bonded to the formula (I
The compound represented by () can be obtained by solid-phase or by introducing a cross-linking functional group into the compound represented by the formula (I) and an insoluble carrier and then performing a chemical reaction for solid-phase. In addition, the carrier here refers to what interposes in order to fix the compound shown by a formula (I) to an insoluble carrier, and although protein can also be used, like the carrier in the immunity antigen mentioned above, It is not necessary to be able to contribute to antibody production against small molecule antigens (haptens). Therefore, it is possible to use an antigen for immunization as a compound represented by the formula (I) including a carrier, and it is also possible to use a protein or a synthetic polymer having no immunogenicity as a carrier. Next, (b) the antibody recognizing the compound represented by formula (I) may or may not have a detectable label. If no detectable label is present, use a secondary antibody with a detectable label. If a detectable label is present, detect with a detection method suitable for the label. It can be carried out. When the detectable label is an enzyme, the enzyme reaction substrate may be further included in a measurement reagent (kit). Preferred combinations of enzymes and substrates have been described above.

(2) When the antibody recognizing the compound represented by formula (I) is immobilized, at least the following elements: (a) the antibody recognizing the compound represented by formula (I) is immobilized A measurement reagent (kit) can be constituted by the insoluble carrier thus prepared; and (b) the labeled compound represented by the formula (I). Here, (a) an insoluble carrier on which an antibody recognizing the compound represented by formula (I) is immobilized can be obtained by physically and chemically immobilizing the antibody.
In addition, (b) the labeled compound represented by the formula (I) can be obtained using a technique well known to those skilled in the art. When a detectable label is provided, detection can be performed by a detection method suitable for the label. When the detectable label is an enzyme, the enzyme reaction substrate may be further included in a measurement reagent (kit). These are the same as in the case of (1).

(3) When both the compound represented by the formula (I) and the antibody recognizing the compound represented by the formula (I) are immobilized, at least the following elements: (a) represented by the formula (I) A measurement reagent (kit) can be composed of an insoluble carrier on which a compound to be immobilized is solidified; and (b) an insoluble carrier on which an antibody recognizing the compound represented by formula (I) is immobilized. (A) The insoluble carrier on which the compound represented by formula (I) is solid-phased is the same as in the case of (1), and (b)
The insoluble carrier on which the antibody recognizing the compound represented by I) is immobilized is the same as in (2) above.

<Particle aggregation inhibition immunoassay method: Especially, latex aggregation inhibition method as an example>

As an embodiment of a measuring reagent (kit) for detecting a compound represented by the formula (I) present in a sample, which is different from the labeled immunoassay method, at least the following elements:
(1A) (a) an antibody recognizing a compound represented by formula (I) and (b) a solid-phased synthetic multivalent antigen,
(2A) (a) latex particles on which an antibody recognizing the compound represented by formula (I) is immobilized, and (b) a synthetic multivalent antigen,
(3A) (a) Latex particles on which an antibody that recognizes the compound represented by formula (I) is immobilized, and (b) a solid-phased synthetic multivalent antigen,
The reagent for measurement (kit) comprised by these can be illustrated. "Synthetic multivalent antigen"
The definition of “solid-phase synthetic multivalent antigen” will be described later.
These measuring reagents (kits) can be suitably used for the latex aggregation inhibition method. (A),
The latex particles used in (b) can be appropriately selected in particle size and type in order to obtain desired performance such as sensitivity improvement. As the material of the latex, any material suitable for carrying an antigen or an antibody may be used. In addition to latex generally used as a main component,
Examples thereof include styrene-butadiene copolymers and (meth) acrylic acid ester polymers. Further, particles made of a material such as metal colloid, gelatin, liposome, microcapsule, silica, alumina, carbon black, metal compound, metal, ceramics or magnetic material can be used instead of latex particles.

Furthermore, as an embodiment of the measuring reagent (kit) for detecting the compound represented by the formula (I) present in a sample different from the above, at least the following elements:
(A) an insoluble carrier on which an antibody recognizing the compound represented by formula (I) is solid-phased; and (b) a labeled reagent represented by formula (I). ):
(B) an antibody that recognizes a labeled compound represented by formula (I); and (b) a reagent for measurement (kit) comprising the compound represented by formula (I) or a synthetic multivalent antigen
Thus, a reagent for measurement (kit) based on the immunochromatography method can be exemplified.

The above-mentioned “synthetic multivalent antigen” is a low molecular antigen (hapten) immunoassay method, particularly a particle aggregation immunoassay method, in order to improve the degree of aggregation. It is similar to what is called a polyhapten or the like. A synthetic multivalent antigen is not limited in its production method or configuration as long as it can function as an agglutinin after multimerizing ofloxacin. A product obtained by polymerizing ofloxacin through a carrier such as an appropriate protein, polyamino acid, peptide, sugar polymer (low molecular polysaccharide or high molecular polysaccharide, etc.), water-soluble synthetic polymer, spacer compound, etc. can be used. The antigen for immunization and the antigen for screening of the present invention also correspond to the synthetic multivalent antigen. The number of molecules (binding ratio) of the compound represented by the formula (I) that binds to one carrier molecule can be adjusted and manufactured in the same manner as in the immunization antigen and screening antigen production methods. The binding ratio may be any as long as it is 2 or more that can be recognized as a multivalent antigen, and can be appropriately selected so as to obtain desired performance as an agglutinin. For example, it is composed of examples described later (a) latex particles in which an antibody recognizing a compound represented by formula (I) is immobilized; and (b) a synthetic multivalent antigen (using bovine serum albumin as a carrier). In the latex agglutination inhibition method using the measuring reagent (kit), the binding ratio is preferably 8 or more, and more preferably 15 or more. This binding ratio is a value at which the optimum numerical value varies depending on the carrier type, the measuring reagent, and the design of the measuring method. A person skilled in the art can construct the measurement reagent after selecting a desired carrier and determining an optimal binding ratio for each carrier.

The “solid-phase synthetic multivalent antigen” has the same purpose and function as the “synthetic multivalent antigen”. Solid-phase synthetic polyvalent antigens are those in which ofloxacin is chemically or physically bound to two or more molecules of an insoluble carrier (such as latex particles) (in this case, via a carrier or a spacer) or the synthetic polyvalent antigen. This is obtained by chemically or physically binding an antigen to an insoluble carrier (such as latex particles).

Hereinafter, the present invention will be described more specifically with reference to examples. However, the scope of the present invention is not limited to the following examples.
[Example 1] Hybridoma preparation and antibody acquisition (I) Materials and methods (1) Preparation of immunizing antigen and screening antigen (i) S-form of the compound represented by formula (I) (hereinafter simply referred to as levofloxacin or 10 mL of 10 mg of LVFX (sometimes referred to as LVFX) (0.1 mol / L phosphate buffer 0.4 mL)
DMSO 0.2 mL, purified water 1.4 mL) to obtain an LVFX solution. Incidentally, as the S form of the compound represented by the formula (I), in the examples of the present application, all of levofloxacin 1 /
Dihydrate ([(−)-(S) -9-fluor-2,3-dihydro-3-methyl-
10- (4-methyl-1-piperazinyl) -7-oxo-7H-pyrido [
1,2,3-de] [1,4] benzoxazine-6-carboxylicaci
d hemihydrate]).
(Ii) 2 mg of BSA powder or 2 mg of transferrin powder was added to the LVFX solution, each was dissolved while gently rotating, then left on ice for 5 minutes, and two types of LV
An FX protein mixture was obtained.
(Iii) Next, 160 mg of water-soluble carbodiimide (WSC) was added as a cross-linking agent to each LVFX protein mixed solution, dissolved, and then incubated for 70 hours while gently rotating at 4 ° C. in the dark.
(Iv) Thereafter, dialysis was performed in PBS (pH 7.2) at 4 ° C. for 2 days.
(V) The dialyzed solution was collected and the absorbance at 330 nm was measured to determine the LVFX concentration, and the coupling rate (LVFX-protein binding ratio) was confirmed.

(2) Immunization and test blood collection The LVFX-BSA coupling product (LVFX-BSA) is dissolved in PBS, mixed with an adjuvant 1: 1, and mixed with a connected syringe to prepare an emulsion. Was used as an antigen for immunization.
Three female BALB / c mice (ML-1, ML-2: 7 weeks old, ML-3: 11
Each week), 10 μg (ML−) of the antigen for immunization as a single dose per animal.
1), 20 μg (ML-2) and 40 μg (ML-3) were subcutaneously administered. One week later, the same dose was administered again subcutaneously.
After 14 days from the start of immunization, mouse antiserum was collected from the fundus of each mouse, and antigen-immobilized E described later was collected.
The antibody titer in the antiserum was confirmed by the LISA method. Furthermore, in order to confirm the reactivity of the antibody in the antiserum to free levofloxacin, free levofloxacin was allowed to coexist in the reaction system at 2 μmol / L, 10 μmol / L, and 50 μmol / L in a competitive ELISA method described later. The reactivity of each antiserum under conditions was examined.
In any ELISA method, normal serum collected from the fundus of an unimmunized mouse was used as a control.

(3) Cell fusion Five days after the test blood collection, the mouse ML-1 was intravenously injected with 10 μg LVFX-BSA for final immunization. Three days after the final immunization, the spleen was removed and cell fusion was performed by a conventional method using polyethylene glycol. As myeloma cells, SP2 / O was used. The obtained fused cells were suspended in RPMI 1640 medium containing hypoxanthine-aminopterin-thymidine (HAT) and 15% fetal calf serum so as to be 2.5 × 10 ⁶ / mL as spleen cells. Was dispensed at 0.2 mL each. This was cultured at 37 ° C. in a 5% CO ₂ incubator.

(4) Screening As a primary screening 11 days after cell fusion, antigen-immobilized ELISA using culture supernatant
The A method was performed, and wells that showed high reactivity to the LVFX-transferrin coupling product (LVFX-transferrin) were selected as primary positive wells. Cells in the primary positive well were passaged in 48-well plates.
Two days after passage, as a secondary screening, a competitive ELISA was performed using the culture supernatant,
Wells that showed high reactivity to free levofloxacin were selected as secondary positive wells.
Cell lines selected in the secondary screening were subjected to competitive ELISA with levofloxacin concomitant drugs, similar compounds, and metabolites as the tertiary screening. Furthermore, using the culture supernatant of the cell line selected by the third screening, when human serum coexists in the reaction system of the competitive ELISA method with free levofloxacin or when levofloxacin is pre-incubated with serum, It was investigated whether the reactivity was affected.

(5) Cloning and immunoglobulin (antibody) collection Ten hybridomas selected in the third screening were cloned by the limiting dilution method. Next, in order to collect the immunoglobulin (antibody) produced by each hybridoma, 2
Pristane 0.5mL prior week to 12-week-old female BALB / c mice that had been injected intraperitoneally, hybridomas were intraperitoneally administered in an amount of several 0.5 × 10 ⁶ cells cells. After 14 days, ascites was collected and centrifuged to obtain a supernatant. Equal amount of buffer for adsorption (3 mol / LNaC)
l, 1.5 mol / L Glycine-NaOH buffer, pH 8.5) and then filtered. The filtrate was passed through a protein A column equilibrated with an adsorption buffer, and the antibody in the filtrate was adsorbed onto the column and then eluted with 0.1 mol / L citrate buffer (pH 3.0). . The eluate was neutralized with 1 mol / LT Tris-HCl buffer (pH 8.0), dialyzed with PBS, and the antibody was collected.

(6) Confirmation of subclass Subclass determination kit (ZY) for 10 kinds of collected immunoglobulins (antibodies)
The subclass was confirmed using MED).

(7) Preparation of ELISA plate LVFX-transferrin dissolved in PBS and adjusted to a concentration of 1 μg / mL was used as a screening antigen, and 50 μL / well was immobilized on a 96-well plate and allowed to stand overnight at 4 ° C. . After washing 3 times with PBST (0.05% Tween20-PBS) (400 μL /
well) and blocking solution (3% skim milk-PBST) were dispensed at 100 μL / well, and allowed to stand at room temperature for 1 hour for blocking to prepare an ELISA plate. The ELISA plate was washed three times with PBST, and then each reagent was added and used for each ELISA method test described in the Examples.

(8) Antigen-immobilized ELISA method (i) 50 μL / well of mouse antiserum or fusion cell culture supernatant diluted in 8 stages of 1% BSA-PBST in 100-fold to 5-fold increments on an ELISA plate It dispensed at a time and allowed to stand at room temperature for 1 hour.
(Ii) After washing 3 times with PBST, HRP-GtF (ab ′) ₂ -Anti-Mouse Ig
A solution obtained by diluting s (Biosource, AMI4404) 5000 times with 1% BSA-PBST was dispensed at 50 μL / well and allowed to stand at room temperature for 1 hour.
(Iii) After washing 3 times with PBST, OPD coloring solution (OPD 2 mg / mL, hydrogen peroxide 0
. (Dissolved in pH 5.0 citrate buffer at a concentration of 02%) (50 μL / well)
It was left to stand at room temperature for 10 minutes.
(Iv) After 0.75 mol / L sulfuric acid was dispensed by 50 μL / well to stop the reaction, the absorbance at 492 nm was measured with a plate reader.

(9) Preparation of compound solution used in competitive ELISA method As compounds used in competitive ELISA method, levofloxacin, concomitant drug of levofloxacin described later, new quinolone antibacterial agent which is a similar compound of levofloxacin, metabolite of levofloxacin and ofloxacin (racemate) I chose. A solution that can easily dissolve these compounds is purified water, PBST, DMSO, methanol, 0.1 mol / L HCl.
Or 0.1 mol / L NaOH. 0.1 mol as solution
When / L HCl or 0.1 mol / L NaOH is selected, after dissolving the compound in these, immediately dilute 50-fold with 1% BSA-PBST, and check that the pH is near neutrality with pH test paper. confirmed. The dissolved compound has a compound concentration of 0.01 μmol / L, 0.1
In order to be μmol / L, 1 μmol / L, 10 μmol / L, 100 μmol / L,
Dilute serially with 1% BSA-PBST and use in competitive ELISA. For example, levofloxacin was dissolved in purified water to 1 mmol / L, and further diluted serially with 1% BSA-PBST and used in the competitive ELISA method.

<Levofloxacin concomitant drug tested for cross-reactivity>
Diclofenac sodium, nabumetone, flurbiprofen, ketoprofen, loxoprofen sodium, oxaprozin, naproxen, ibuprofen, carbocysteine, salicylamide, acetaminophen, anhydrous caffeine, methylenedisalicylic acid, promethazine, and theophylline <cross reactivity was tested Analogs of levofloxacin>
Ciprofloxacin, tosufloxacin, gatifloxacin, sparfloxacin, fleroxacin, lomefloxacin, norfloxacin, enoxacin, moxifloxacin, and pazufloxacin <metabolite of levofloxacin tested for cross-reactivity>
N-oxide and demethylated <ofloxacin>
S form and R form mixture of the compound represented by formula (I) (composition ratio 1: 1)

(10) Competitive ELISA method (i) Each compound solution prepared in the preparation of the compound solution used in the (9) competitive ELISA method was dispensed into an ELISA plate at 25 μL / well.
(Ii) Next, each mouse antiserum diluted 1000-fold with 1% BSA-PBST or culture supernatant of fused cells was dispensed at 25 μL / well and allowed to stand at room temperature for 1 hour.
The subsequent operations were performed in the same manner as in steps (ii) to (iv) of the above-described (8) antigen-immobilized ELISA method.

(11) Evaluation of effect of serum in competitive ELISA method using the antibody of the present invention (i) Human serum was diluted with 1% BSA-PBST to prepare 5% human serum. The human serum and plasma used in each example of the present invention are derived from volunteer blood collected with consent.
(Ii) 2.0 μmol / L, 0.2 μmol / L, 0.02 μmo using 5% human serum
l / L levofloxacin was prepared and used as human serum reagent a. As a control reagent,
2.0 μmol / L, 0.2 μmol / L, 0.02 μm using 1% BSA-PBST
ol / L levofloxacin was prepared.
(Iii) 25 μL of human serum reagent a or control reagent on the ELISA plate
/ Well dispensed.
(Iv) Next, the culture supernatant of the fused cells was dispensed at 25 μL / well and allowed to stand at room temperature for 1 hour.
The subsequent operations were performed in the same manner as in steps (ii) to (iv) of the above-described (8) antigen-immobilized ELISA method.

(12) Evaluation of the effect when a sample in which free levofloxacin was previously incubated with human serum was measured by a competitive ELISA method (i) A levofloxacin solution dissolved in purified water was diluted 100-fold with human serum to 30 μmo
A 1 / L levofloxacin solution was prepared and incubated at 37 ° C. for 0, 15, 60 minutes.
(Ii) After incubation for each time, 1% of the 30 μmol / L levofloxacin solution was added.
Diluted 15 times, 150 times and 1500 times with BSA-PBST to obtain human serum reagent b.
(Iii) 25 μL / well of human serum reagent b was dispensed onto the ELISA plate.
(Iv) Next, the culture supernatant of the fused cells was dispensed at 25 μL / well and allowed to stand at room temperature for 1 hour.
The subsequent operations were performed in the same manner as in steps (ii) to (iv) of the above-described (8) antigen-immobilized ELISA method.

(13) Digitization of reaction (i) From the measured absorbance, first, the reactivity (%) at each addition concentration of each compound was calculated using the following formula (1).
Reactivity (%) = [Abs. (X)] / [Abs. (0)] × 100 (1)
)
Abs. (X):
(Absorbance at compound concentration x μmol / L) − (Absorbance at antibody 0 μg / mL)
Abs. (0):
(Absorbance at compound concentration 0 μmol / L) − (Absorbance at antibody 0 μg / mL)
(Ii) Next, for each compound, create a graph plotting the relationship between additive concentration and reactivity,
The concentration of each compound added when the reactivity reached 50% was determined. This concentration is 50% inhibitory concentration (
IC ₅₀ ).
(Iii) The crossing rate (%) of each antibody with respect to each compound was determined from the IC ₅₀ by the following formula. Based on the calculated crossover rate, a criterion for determining the strength of crossreactivity of each antibody against each compound was set.
Crossing rate (%) = [IC ₅₀ of each compound] / [IC ₅₀ of levofloxacin] × 100
... Formula (2)
Strong cross reactivity: Cross rate 80% or more to 100%
During cross-reactivity: Crossing rate: 40% to less than 80% Cross-reactivity weak: Crossing rate: 1% to less than 40% No cross-reaction: Crossing rate: 0% to less than 1% Cross-reactivity of each antibody to ofloxacin The criteria for determining the strength of sex were set as follows.
Reacts strongly with S form: Crossing rate is less than 100% S form reacts with R form equivalent: Crossing rate is 100%
Reacts strongly with R-form: Crossing rate exceeds 100%

(II) Results (1) Preparation of immunizing antigen and screening antigen The LVFX-protein binding ratio of the prepared immunizing antigen and screening antigen was LV
FX-BSA was 12.0 and LVFX-transferrin was 13.9, both showing high values. The value of the binding ratio is calculated by dividing the concentration of LVFX after dialysis by the concentration of BSA or transferrin before dialysis, and represents the number of LVFX molecules bound per molecule of BSA or transferrin.
(2) Results of antigen-immobilized ELISA test in test blood collection As a result of test blood sampling and antibody titer in each mouse antiserum examined by antigen-immobilized ELISA method, high antibody in all three mouse antisera The value was confirmed (FIG. 1). Since the coupled antigen is different between the screening antigen and the immunization antigen immobilized on the ELISA plate, each antibody reacts nonspecifically with the protein portion (in other words, the carrier) of the screening antigen immobilized on the plate. The possibility to do is excluded. Therefore, each mouse antiserum obtained in this example was considered to contain an antibody that specifically recognizes levofloxacin, which is a common part in immunization and screening antigens.
(3) Results of competitive ELISA test in blood collection Test antigen and each mouse anti-antigen when free levofloxacin not bound to protein coexists in the reaction system of competitive ELISA and competes with immobilized antigen. As a result of examining the change in the reaction amount with the antibody in the serum, the reaction amount of the antibody against the screening antigen decreased in any of the three mouse antisera according to the amount of levofloxacin added to the reaction system (FIG. 2). ). Therefore, each mouse antiserum obtained in this example was considered to contain an antibody that recognizes free levofloxacin.

(4) Screening As a result of the primary screening, 63 strains that showed high reactivity to the immobilized LVFX-transferrin were selected as primary positive strains. As a result of secondary screening, 32 strains showing high reactivity with free levofloxacin were obtained as secondary positive strains. As a result of the third screening, 10 strains that did not cross-react with levofloxacin concomitant drugs, similar compounds, and metabolites or that had relatively weak cross-reactivity were selected, and antibodies derived from these 10 strains were further tested.

For the 10 types of antibodies selected by the tertiary screening, human serum was allowed to coexist in the reaction system of the competitive ELISA method, and the influence of serum components on antibody reactivity was examined. The addition of serum could cause free levofloxacin to bind to protein in serum to form conjugated levofloxacin, which may affect the antibody response. In either antibody, control (no serum added) and serum The difference in reactivity when adding was less than 5%.

For the 10 types of antibodies selected by the tertiary screening, free serum ofloxacin was incubated with serum in advance, and human serum reagent b was converted into bound ofloxacin bound to serum protein. It measured as a sample of ELISA method. As a result of determining the reactivity of the antibody by the competitive ELISA method, the difference in reactivity at the incubation time of 15 minutes and 60 minutes was less than 5% compared to the case of the incubation time of 0 minutes.

From the above-mentioned two kinds of test results for examining the effect of serum, the 10 types of antibodies selected by the tertiary screening are free levofloxacin not bound to serum protein even though it is bound levofloxacin bound to serum protein. It was considered that free and bound types in the sample could be detected simultaneously.

(5) Cloning and confirmation of immunoglobulin (antibody) and collection subclass As a result of examining the subclasses of 10 types of antibodies selected in the third screening, 8 out of 10 types are IgG subclasses, and the other 2 types of antibodies are IgA and IgM. Thereafter, only the eight monoclonal antibodies 77201 to 77207 and 77209 whose subclass was IgG were evaluated.
Of these 8 types of antibodies, 7 hybridomas except for one of 77203, which showed some reactivity with levofloxacin demethylated product in Example 2, were designated as independent administrations of hybridomas producing the monoclonal antibodies. Deposited with the National Institute of Advanced Industrial Science and Technology (1st, 1st, 1st East, Tsukuba City, Ibaraki, Japan). The deposit number is as follows.
Antibody number: Deposit number 77201: FERM BP-11010
77202: FERM BP-11011
77204: FERM BP-11012
77205: FERM BP-11013
77206: FERM BP-11014
77207: FERM BP-11015
77209: FERM BP-11016

[Example 2] Cross-reactivity evaluation of monoclonal antibodies produced by each hybridoma (I) Materials and methods (1) Preparation of reagents Each compound used in the competitive ELISA was the same as in Example 1 (I) (9). It was prepared by the operation.
(2) Evaluation of cross-reactivity (competitive ELISA method)
Example 1 (I) (10) Performed in the same manner as the competitive ELISA method. However, the antibodies used were 7 types of monoclonal antibodies (purified IgG: 0.2 μg / mL) selected in Example 1 (II) (5).
). The antibody reactivity and cross-reactivity were also calculated in the same manner as in Example 1 (I) (13) and digitized.

(II) Results (1) Reactivity of each monoclonal antibody against free levofloxacin As shown in FIG. 3, it was confirmed that each antibody reacts with free levofloxacin.

(2) S compound (levofloxacin) of the compound represented by the similar compound, metabolite and formula (I),
Cross-reactivity of racemic body (ofloxacin) which is a 1: 1 mixture of R-form and S-form and R-form Table 1 shows the crossover ratio of each antibody against similar compounds, levofloxacin metabolite and ofloxacin.

77201,7 for the cross-reactivity of each monoclonal antibody to each analogous compound
7202 and 77204 showed cross-reactivity to moxifloxacin. 77205
77207 and 77209 showed some cross-reactivity with fleroxacin, but did not cross-react with all other similar compounds or were weakly cross-reactive.

77201, 77202, 7 for the cross-reactivity of each antibody to ofloxacin
The five types of antibodies, 7204, 77205, and 77207, had the same cross-reactivity to S-form and cross-reactivity to ofloxacin. 77206 was determined to be an antibody that strongly reacts with S-isomer because the cross-reactivity to ofloxacin was 50%. On the other hand, 77209 has a crossing rate to ofloxacin of 250%, and its cross-reactivity to ofloxacin is stronger than that of levofloxacin alone.

The cross-reactivity of each antibody to the levofloxacin metabolite, ofloxacin, is summarized as follows.
77201, 77202, 77204, 77205, 77207: An antibody that reacts with ofloxacin and does not react with N-oxide and demethylated metabolites thereof, and has the formula (I)
That reacts with both S-form (levofloxacin) and R-form of the compound represented by 7777206: An antibody that reacts with ofloxacin and does not react with its metabolite N-oxide and demethylated form and strongly reacts with levofloxacin Antibody 77209: An antibody that reacts with ofloxacin and does not react with its metabolite N-oxide and demethylated form, and strongly reacts with ofloxacin R-form

Furthermore, the cross-reactivity with typical levofloxacin concomitant drugs was examined, and the cross-reactivity for these was less than 0.1%. Therefore, it was determined that each antibody did not respond to a typical levofloxacin combination drug.

[Example 3] Evaluation of influence by serum (competitive ELISA method)
(I) Method and procedure (1) Influence of serum addition "Example 1 (I) (11) Evaluation of the influence of serum on the antibody of the present invention by competitive ELISA"
In the step (iv), the culture supernatant of the fused cells in step (iv)
G, 0.2 μg / mg). In addition, reactivity and cross-reactivity were also evaluated numerically according to Example 1 (I) (13).
(2) Effect of Incubation of Free Levofloxacin and Human Serum [Example 1 (I) (12) Effect of Inhibition of Sample Incubated with Free Levofloxacin and Human Serum by Competitive ELISA Method The operation of “Evaluation” was performed in the same manner except that the culture supernatant of the fused cells was changed to a monoclonal antibody (purified IgG, 0.2 μg / mg). In addition, reactivity and cross-reactivity were also evaluated numerically according to Example 1 (I) (13).

(II) Results (1) Effects of adding serum Human serum was allowed to coexist in the reaction system of the competitive ELISA method to examine the influence of serum components on antibody reactivity. By adding serum, free levofloxacin bound to protein in serum to form bound levofloxacin, which may affect the reactivity of the antibody. The difference in reactivity when serum was added was less than 5%.
(2) Effect of addition of pre-incubated free levofloxacin and human serum Human serum reagent b in which free levofloxacin and serum are pre-incubated to convert free levofloxacin to bound levofloxacin bound to serum protein b
Was measured as a sample of the competitive ELISA method. As a result of determining the reactivity of the antibody by the competitive ELISA method, the difference in reactivity at the incubation time of 15 minutes and 60 minutes was less than 5% compared to the case of the incubation time of 0 minutes.

From the results of (1) and (2) above, it was found that this antibody is not affected by serum proteins in the antigen-antibody reaction. Therefore, this antibody is an antibody that can be used for blood drug concentration measurement.

[Example 4] Immunological measurement method of levofloxacin in sample using antibody of the present invention (I) Method and procedure (1) Preparation of reagent Dissolve levofloxacin powder in purified water to 1 mmol / L A product levofloxacin solution (standard solution) was used. The standard solution was dispensed into a serum tube and then stored frozen at −80 ° C. until use.

(2) Preparation of calibration curve (i) A standard solution was prepared with 1% BSA-PBST from 2 μmol / L to 0.0625 μmol /
Dilute in 6 steps up to L to obtain a standard sample.
(Ii) Dispensing 25 μL / well of the standard sample onto an ELISA plate;
77206 antibody (purified IgG, 0.1 μg / mL, 1% BSA-PBST) at 25 μL /
Each well was dispensed and allowed to stand at room temperature for 1 hour.
The subsequent operations were carried out in the same manner as steps (ii) to (iv) of Example 1 (I) (8) Antigen-immobilized ELISA method.

(3) Dilution linearity test (i) Dilute the standard solution with human serum to an appropriate concentration, and add levofloxacin-containing human serum to 3
Kinds were prepared.
(Ii) Each of the levofloxacin-containing human sera was first treated with 1% BSA-PBST for 11
The sample was diluted 2-fold and then diluted 2 times to 704-fold to obtain a diluted linearity test sample.
(Iii) 25 μL / well of the diluted linearity test sample was dispensed onto an ELISA plate, and then the 77206 antibody (purified IgG, 0.1 μg / mL, 1% BSA-PBST
) Was dispensed at 25 μL / well and allowed to stand at room temperature for 1 hour.
The subsequent operations were carried out in the same manner as steps (ii) to (iv) of Example 1 (I) (8) Antigen-immobilized ELISA method. The measured absorbance was converted into a concentration using a calibration curve, and plotted on a graph with the serum dilution rate on the x-axis and the concentration-converted value on the y-axis.
0/100). In addition, the correlation coefficient between the concentration conversion value and the serum dilution rate was determined.

(4) Simultaneous reproducibility test (i) Standard solution is 30 μmol / L, 10 μmol / L, 6 μm with 1% BSA-PBST
After diluting to ol / L and diluting 11 times with serum, it was further diluted 2 times with 1% BSA-PBST to obtain samples for simultaneous reproducibility test (sample A, sample B, sample C).
(Ii) 25 μL / well of the sample for simultaneous reproducibility test was dispensed on an ELISA plate, followed by 77206 antibody (purified IgG, 0.1 μg / mL, 1% BSA-PBST)
Was dispensed at 25 μL / well and allowed to stand at room temperature for 1 hour.
The subsequent operations were carried out in the same manner as steps (ii) to (iv) of Example 1 (I) (8) Antigen-immobilized ELISA method. The measured absorbance was converted into a concentration using a calibration curve. Each simultaneous reproducibility test sample was measured eight times, and the average, standard deviation, and coefficient of variation of the measured values were obtained.

(5) Addition / recovery test (i) The standard solution was diluted to an appropriate concentration with 1% BSA-PBST, diluted 11-fold with serum, and then further diluted 2-fold with 1% BSA-PBST. A sample was used.
(Ii) 25 μL / well of the sample for addition recovery test was dispensed to the ELISA plate, and then 77206 antibody (purified IgG, 0.1 μg / mL, 1% BSA-PBST) was dispensed at 25 μL / well. And left at room temperature for 1 hour.
The subsequent operations were carried out in the same manner as steps (ii) to (iv) of Example 1 (I) (8) Antigen-immobilized ELISA method. The measured absorbance was converted to a concentration using a calibration curve, and plotted on a graph with the theoretical value as the x-axis and the concentration converted value as the y-axis. Moreover, the regression formula and correlation coefficient of the concentration conversion value and the theoretical value were obtained.

(II) Results (1) Preparation of calibration curve Using a standard sample, a calibration curve in the range of 0.0625 μmol / L to 2 μmol / L was prepared. In the said range, the calibration curve showed favorable linearity, and it was confirmed that the measuring method of the present invention can be used for quantitative measurement of the compound represented by the formula (I) in the sample. (FIG. 4).

(2) Dilution linearity test The correlation coefficient between the concentration conversion values of three types of dilution linearity test samples and the serum dilution rate is 0.9.
It was 9 or more, and showed good dilution linearity (FIG. 5). Using the antibody of the present invention, it was shown that a measurement system that is not affected by the serum component derived from the sample can be constructed.

(3) Simultaneous reproducibility test Three samples of the simultaneous reproducibility test were measured at the same time eight times, and all samples showed high simultaneous reproducibility with a coefficient of variation (CV%) of less than 10% ( Table 2).

(4) Measurement of Sample with Known Concentration The regression equation between the theoretical value and the converted value of the sample for addition recovery test was y = 1.080x + 0.021, and the correlation coefficient was 0.993 (FIG. 6). From the above, it was shown that the measurement method using the antibody of the present invention can accurately measure the concentration of the compound represented by the formula (I) in the biological sample.

[Example 5] When biological sample is saliva (I) Method and procedure (1) Preparation of reagent The standard solution prepared in Example 4 (I) (1) was used.
(2) Competitive ELISA (i) 10%, 5%, 2% human saliva dilutions were made with 1% BSA-PBST.
(Ii) The standard solution was diluted to 0.2 μmol / L with each concentration of human saliva diluted solution to prepare a human saliva sample. A sample containing no human saliva (0%) was used as a control.
(Iii) A human saliva sample was dispensed at 25 μL / well into an ELISA plate.
(Iv) The 77201 antibody (purified IgG, 0.2 μg / mL, 1% BSA-PBST
) Was dispensed at 25 μL / well and allowed to stand at room temperature for 1 hour.
The subsequent operations were performed in the same manner as in steps (ii) to (iv) of Example 1 (I) (8) antigen-immobilized ELISA method.

(II) Results (1) When the biological sample is saliva The difference in reactivity is less than 5% when the saliva concentration in the measurement sample is 0% and when the saliva concentration is 10%, 5%, 2% And was not affected by salivary components (FIG. 7). In saliva, there are components that inhibit the immune reaction system such as lysozyme and mucopolysaccharide, and it is considered that epitopes in free antigen may be covered by components in the saliva. It was shown that the measurement method using this antibody can accurately measure the concentration of the compound represented by the formula (I) in the biological sample without being affected by the saliva component.

[Example 6] Evaluation of influence by plasma (competitive ELISA method)
We examined the effects of plasma containing a larger amount and amount of protein than serum.
(I) Method and Procedure (1) Preparation of Reagents Each compound used in the competitive ELISA method was prepared in the same manner as the preparation of the reagent in Example 1 (I) (9).
(2) Evaluation of influence of plasma by competitive ELISA method (i) 10% human plasma was prepared with 1% BSA-PBST.
(Ii) 0.4 μmol / L, 0.2 μmol / L, 0.01 μm using 10% human plasma
ol / L levofloxacin was prepared and used as human plasma reagent a. As a control reagent,
0.4 μmol / L, 0.2 μmol / L, 0.01 μm using 1% BSA-PBST
ol / L levofloxacin was prepared.
(Iii) 25 μL / ml of human plasma reagent a or control reagent on the ELISA plate
Wells were dispensed.
(Iv) The 77206 antibody (purified IgG, 0.2 μg / mL, 1% BSA-PBST)
) And dispensed at room temperature for 1 hour.
The subsequent operations were carried out in the same manner as steps (ii) to (iv) of Example 1 (I) (8) Antigen-immobilized ELISA method.

(II) Results (1) Effects of plasma addition It was expected that free antigen binds to plasma protein and becomes bound antigen by plasma addition, and competitive reaction is expected to be inhibited. (No plasma added)
The difference in reactivity when plasma and plasma were added was less than 5% (FIG. 8). This antibody is not affected by plasma proteins in antigen-antibody reaction, and is an antibody that can be used for blood drug concentration measurement.

[Comparative example]
(1) Properties of conventional antibodies (effects of plasma components)
(I) Method and procedure The method described in Patent Document 2 was partially modified.
(I) 20 μg / mL in a 96-well plate with 0.1 mol / L carbonate buffer (pH 9.5)
100 μL / well of the goat anti-rabbit IgG prepared above was added, incubated at room temperature for 2 hours to solidify the primary antibody, and the plate was washed with a washing solution (0.05% Tween 20, 50 m).
It was washed 3 times with mol / L Tris-HCl, pH 7.4).
(Ii) 50 mmol / L Tris-HCl buffer (pH 7.4) 3 containing 1% BSA
After adding 00 μL / well and incubating at room temperature for 2 hours, the plate was washed with washing solution.
Washed twice.
(Iii) Next, an anti-levofloxacin rabbit antiserum diluted to an appropriate concentration with 50 mmol / L Tris-HCl buffer (EIA buffer) containing 0.5% BSA was added and incubated at room temperature for 2 hours to Anti-levofloxacin antibody in levofloxacin rabbit antiserum was captured by the primary antibody. Thereafter, the plate was washed 3 times with a washing solution.
(Iv) Further, 50 μL of alkaline phosphatase-labeled antigen diluted 50 times with EIA buffer and 50 μL of 10 μg / mL levofloxacin solution diluted with EIA buffer containing 10% human plasma or EIA buffer not containing human plasma were added to each well. Incubated for 2 hours at room temperature.
(V) Wash the plate 3 times with washing solution and add 100 p-nitrophenyl phosphate substrate solution.
After adding μL and incubating at room temperature for 30 minutes, the reaction was stopped by adding 25 μL of 1.6 mol / L sodium hydroxide solution, and the absorbance at 405 nm was measured.

(II) Results The reactivity of the sample to which plasma was added was approximately twice that of the sample without plasma (FIG. 9). This is presumably because the competitive reaction was inhibited as a result of the antibody becoming unable to recognize the epitope in levofloxacin due to the plasma protein binding to free levofloxacin to form bound levofloxacin. On the other hand, it is considered that the enzyme-labeled antigen in the reaction solution did not affect the antigen-antibody reaction because the labeled enzyme bound to the antigen interferes with the binding between plasma protein and levofloxacin.

[Example 7] Alternative method of competitive ELISA method (1-step competitive ELISA method)
The competitive ELISA method described in the step of Example 1 (I) (8) antigen-immobilized ELISA method was
It is also possible to carry out the detection by the following method in which detection is performed in one step by labeling the antibody with HRP in advance.
(I) Methods and procedures (1) Preparation of HRP-labeled antibodies (i) Seven types of monoclonal antibodies, antibodies 77201, 77202, 77204, 772
05, 77206, 77207, and 77209 were dialyzed in 0.1 mol / L sodium bicarbonate buffer (pH 9.3) at 4 ° C. for 2 days. The solution after dialysis was collected, and the antibody concentration was confirmed by measuring the absorbance at 280 nm.
(Ii) 50 mg of HRP (Toyobo, PEO-301) in 5 mmol / L acetate buffer (pH 4)
. 5) Dissolved in 5 mL. 2 parts of sodium periodate aqueous solution (100 mg / mL)
1.5 μL was added, and the mixture was allowed to stand at room temperature for 30 minutes under light shielding conditions.
(Iii) PD-10 column (Amersham Biosciences, 17-
0851-01) (using 5 mM acetate buffer (pH 4.5) as eluent), and the dark green solution fraction was collected. The concentration of activated HRP contained in this solution was confirmed by measuring the absorbance at 280 nm.
(Iv) 0.1 mol / L of the antibody prepared in (i) and the activated HRP prepared in (iii)
Diluted to 1 mg / mL with sodium bicarbonate buffer (pH 9.3). 2 solutions
50 μL each was mixed and allowed to stand at room temperature for 1 hour under light shielding conditions.
(V) 10 μL of aqueous sodium borohydride solution (2 mg / mL) was added,
The mixture was allowed to stand at room temperature for 15 minutes.
(Vi) Subsequently, 510 μL of a saturated aqueous ammonium sulfate solution was added, and the mixture was allowed to stand on ice for 1 hour under light-shielding conditions.
(Vii) The obtained solution was centrifuged at 10000 rpm for 10 minutes at 4 ° C. to obtain an antibody pellet.
(Viii) Redissolving the antibody pellet with 500 μL of PBS (pH 7.2),
Dialysis was performed in PBS (pH 7.2) for 2 days at ° C.
(Ix) The concentration of the HRP-labeled antibody was confirmed by collecting the solution after dialysis and measuring the absorbance at 280 nm.

(2) One-step competitive ELISA method (i) The levofloxacin solution of each concentration prepared in the same manner as the preparation of the compound solution used in Example 1 (I) (9) competitive ELISA method was added to an ELISA plate at 25 μL / well. Dispensed one by one.
(Ii) Next, the HRP-labeled antibody prepared in (1) Preparation of HRP-labeled antibody was treated with 1% BSA-
The antibody solution diluted 70-fold to 3500-fold with PBST was dispensed at 25 μL / well and allowed to stand at room temperature for 1 hour.
The subsequent operations were carried out in the same manner as in steps (iii) to (iv) of Example 1 (I) (8) antigen-immobilized ELISA method.

(II) Results As a result of free levofloxacin not bound to the protein coexisting in the reaction system of the one-step competitive ELISA method and competing with the immobilized antigen, levofloxacin was released into the reaction system in any HRP-labeled antibody. The reaction amount of the HRP-labeled antibody against the immobilized antigen was decreased according to the amount added (FIG. 10). Therefore, the one-step competitive ELISA shown in this example was considered useful as an immunological measurement method for the compound represented by formula (I) in the sample.

[Example 8] Latex aggregation inhibition method (antibody-immobilized latex system)
This example shows the present invention (20),
“The antibody according to any one of the present invention (1) to the present invention (11) immobilized on a solid phase is competitively reacted with a synthetic multivalent antigen and a compound represented by the formula (I) in a sample. A method for immunological determination of a compound represented by formula (I) in a sample, ”
As a response to this, a latex agglutination inhibition method (antibody-immobilized latex system), which is one of the particle agglutination inhibition methods, was tested.

(I) Method and Procedure (1) Preparation of Reagent (i) Example 1 (I) (1) LVFX-BSA (binding ratio 18) prepared by the method described in Preparation of immunizing antigen and screening antigen is 1 20 mmol to 0.0 μg / mL
/ L Tris buffer (pH 7.0, containing 500 mmol / L sodium chloride, 1% BSA) was used as the first reagent. The first reagent includes “the antibody according to any one of the present invention (1) to the present invention (11) immobilized on a solid phase” in the present invention (20).
(Ii) A suspension of 1% latex (manufactured by Sekisui Chemical Co., Ltd.) having an average particle size of about 200 nm is added to 1.5 mL of 20 mmol / L Tris buffer (pH 8.5) containing 0.8 mg / mL of monoclonal antibody 77209. .5 mL was added and stirred at 4 ° C. for 2 hours. Subsequently, 3.0 mL of 20 mmol / L Tris buffer (pH 8.5) containing 0.1% BSA was added, and the mixture was stirred at 4 ° C. for 1 hour. After centrifugation at 13,000 rpm for 35 minutes at 4 ° C., the supernatant is removed and 5 mmo of the same amount as the removed amount is removed.
Resuspended in 1 / L MOPS buffer (pH 7.0, containing 0.1% BSA). After ultrasonic dispersion (Nissei Ultrasonic Generator), the resulting solution was heated at 50 ° C. for 1 hour. After cooling, the solution was diluted with a 5 mmol / L MOPS buffer (pH 7.0) so that the absorbance at a wavelength of 600 nm was 3 Abs, and used as a second reagent.
(Iii) Example 1 (I) (9) Concentrations of 0.0 μg / mL, 1.0 μg / mL, 2.5 μg / mL, 5.0 μg / mL in the same manner as the preparation of the compound solution used in the competitive ELISA method 10
μg / mL and 20 μg / mL levofloxacin aqueous solutions were prepared. Separately, a concentration of 0.0 μm was obtained in the same manner as in the preparation of the compound solution used in Example 1 (I) (9) competitive ELISA.
g / mL, 10 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL, 15
Concentrated levofloxacin standard solution of 0 μg / mL and 200 μg / mL was prepared. The concentrated levofloxacin standard solution is diluted 10-fold with human serum, human plasma or human saliva, and levofloxacin concentrations of 0.0 μg / mL, 1.0 μg / mL, 2.5 μg / mL, 5.0 μg /
mL, 10 μg / mL, 15 μg / mL, and 20 μg / mL levofloxacin-containing human serum, human plasma, or human saliva were prepared.

(2) Measurement procedure Each levofloxacin solution was measured using a general-purpose Hitachi 7170S automatic analyzer.
Specifically, after adding 150 μL of the first reagent to 2.5 μL of each sample solution, warming at 37 ° C. for 5 minutes,
Further, 150 μL of the second reagent was added, and the amount of change in absorbance at 600 nm at photometric points 19 to 34 was measured under 37 ° C. heating.

(II) Results First, the levofloxacin aqueous solution was measured, and the change in absorbance with respect to each levofloxacin concentration was plotted (FIG. 11). The absorbance decreased according to the amount of levofloxacin added to the reaction system. Subsequently, after preparing a calibration curve using a spline function, each concentration of the levofloxacin-containing human serum or human plasma was measured, and the measured value was calculated from the calibration curve. In this measurement range, the theoretical value and the measured value of the levofloxacin solution concentration showed a good correlation (FIG. 12).
13). On the other hand, the levofloxacin-containing saliva was measured, and the change in absorbance with respect to each levofloxacin concentration was plotted. The absorbance decreased according to the amount of levofloxacin added to the reaction system (FIG. 14).
From the above, the latex aggregation inhibition method using the antibody-immobilized latex shown in this Example is
It was confirmed that it can be used for quantitative measurement of the compound represented by the formula (I) in serum, plasma and saliva samples.

[Example 9] Latex aggregation inhibition method (antigen-immobilized latex system)
This example shows the present invention (21),
“The antibody according to any one of the present invention (1) to the present invention (11) is competitively reacted with an immobilized synthetic multivalent antigen and a compound represented by the formula (I) in a sample. And an immunological measurement method for a compound represented by formula (I) in a sample. "
In response to the above, a latex agglutination inhibition method (antigen-immobilized latex system), which is one of the particle agglutination inhibition methods, was tested.

(I) Method and procedure (1) Preparation of reagent (i) Monoclonal antibody 77206 is 5 mmol / L M so as to be 5.2 mg / mL.
Diluted with OPS buffer (pH 7.0) to obtain the first reagent.
(Ii) 10 mmol / L citrate-hydrogen phosphate containing 20 μg / mL of LVFX-BSA (binding ratio 3) prepared by the method described in Example 1 (I) (1) Preparation of antigen for immunization and antigen for screening To 3.0 mL of disodium buffer (pH 5.5, containing 0.8% BSA), add 3.0 mL of a 1% latex (manufactured by Sekisui Chemical Co., Ltd.) suspension having an average particle size of about 210 nm at 4 ° C. Stir for 2 hours. After centrifugation at 13,000 rpm for 30 minutes at 4 ° C., the supernatant was removed and resuspended in 5 mmol / L MOPS buffer (pH 7.0, containing 0.1% BSA) in an amount equal to the removed amount. After ultrasonic dispersion, the resulting solution had an absorbance of 1 at a wavelength of 280 nm.
. It diluted with 5 mmol / LMOPS buffer (pH 7.0) so that it might become 1 Abs, and it was set as the 2nd reagent. The second reagent includes “(b) a synthetic polyvalent antigen obtained by immobilizing two or more molecules of an antigen carrier complex containing a compound represented by formula (I) on a solid phase” in the present invention (21). It is a waste.
(Iii) Example 1 (9) Levofloxacin aqueous solutions having concentrations of 0.0 μg / mL, 5.0 μg / mL, 10 μg / mL, and 20 μg / mL were prepared in the same manner as the preparation of the compound solution used in the competitive ELISA method.

(2) Measurement procedure The levofloxacin aqueous solution of each concentration was measured using a general-purpose Hitachi 7170S type automatic analyzer. Specifically, 4 μL of levofloxacin aqueous solution of each concentration was added to 20 μL of the first reagent, followed by heating at 37 ° C. for 5 minutes, and after addition of 180 μL of the second reagent, absorbance at 700 nm at 37 ° C. and photometry points 19 to 34 The amount of change was measured.

(II) Results The levofloxacin aqueous solution was measured, and the amount of change in absorbance with respect to each levofloxacin concentration was plotted. In this measurement range, the plot approximation formula showed good linearity, confirming that the measurement method of the present invention can be used for quantitative measurement of the compound represented by formula (I) in the sample (FIG. 15).

[Example 10] Examination of synthetic multivalent antigen (binding ratio) in latex aggregation inhibition method (antibody-immobilized latex system)
“The antibody according to any one of the present invention (1) to the present invention (11) immobilized on a solid phase is competitively reacted with a synthetic multivalent antigen and a compound represented by the formula (I) in a sample. A method for immunological determination of a compound represented by formula (I) in a sample, ”
1 examines the ofloxacin binding ratio in the “synthetic multivalent antigen”.

(I) Methods and Procedures (1) Preparation of Reagents 2.2, 5.4, 8.7 as levofloxacin solutions in the method described in Example 1 (I) (1) Preparation of immunizing antigen and screening antigen 11.9, 15.2, 18.
4, Coupling reaction with BSA was performed using 21.7 mg / 2 mL solution. The LVFX-BSA binding ratio of the obtained coupled product was determined by measuring the absorbance in Example 1 (I) (1) (v).
(2) Measurement procedure Each LVFX-BSA was used as a synthetic polyvalent antigen, and the method described in Example 8 (I) latex aggregation inhibition method (antibody-immobilized latex system) was used as a sample in Example 1 (I) ( 9) Concentration of 0.0 μg / mL prepared by the same method as the preparation of the compound solution used in the competitive ELISA method
16.0 μg / mL levofloxacin aqueous solution was measured. Subsequently, the difference in absorbance of each reaction when the levofloxacin concentration was 0.0 μg / mL and 16.0 μg / mL was calculated. A graph for the binding ratio was created.

(II) Results The binding ratio of the obtained coupling product was determined by using the concentration of levofloxacin solution used (mg / 2 m
L) ⇒The following was shown in the form of the coupling ratio. 2.2⇒3.9, 5.4⇒5.0, 8.7⇒
6.2, 11.9⇒8.1, 15.2⇒10.2, 18.4⇒13.0, 21.7⇒16
. 7. From this, depending on the amount of LVFX reacted with one molecule of BSA carrier, LVFX-
It was confirmed that the BSA binding ratio increased (FIG. 16).
Next, when the difference in absorbance between the levofloxacin concentrations of 0.0 μg / mL and 16.0 μg / mL was determined and a graph for the binding ratio was created, the absorbance difference increased with the increase in the binding ratio of LVFX-BSA. In the latex aggregation inhibition method, the absence of antigen in the sample (
It can be said that the antigen in the sample can be measured with higher sensitivity as the difference between the absorbance in the case of concentration 0) and the absorbance in the case where the antigen is present in the sample is larger. Under the conditions of this example, it was found that good sensitivity was obtained when the coupling ratio was 8 to 15 and that the coupling ratio was 15 or more (FIG. 17).

The present invention relates to an antibody against ofloxacin and a method for producing the same. The present invention also relates to an immunoassay method using these antibodies, for example, a radioimmunoassay method,
The present invention relates to enzyme immunoassay and particle aggregation inhibition immunoassay. By using the present invention, it is possible to quickly and accurately measure the abundance of ofloxacin, a powerful antibacterial agent, in the clinical setting.

[Reference to deposited biological materials]
(1) Antibody number 77201
The name and address of the depository that deposited the biological material AIST National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center 1-chome, East 1-chome, Tsukuba City, Ibaraki Prefecture, Japan 6 (zip code 305-8566)
Date of deposit of biological materials at Loi depository, September 11, 2007 (original deposit date)
September 5, 2008 (Date of transfer to deposit under the Budapest Treaty by original deposit)
Deposit number FERM BP-11010 attached to the depositary by the high depository
(2) Antibody No. 77202
The name and address of the depository that deposited the biological material AIST National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center 1-chome, East 1-chome, Tsukuba City, Ibaraki Prefecture, Japan 6 (zip code 305-8566)
Date of deposit of biological materials at Loi depository, September 11, 2007 (original deposit date)
September 5, 2008 (Date of transfer to deposit under the Budapest Treaty by original deposit)
Deposit number FERM BP-11011 attached to the depositary by the high depository
(3) Antibody No. 77204
The name and address of the depository that deposited the biological material AIST National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center 1-chome, East 1-chome, Tsukuba City, Ibaraki Prefecture, Japan 6 (zip code 305-8566)
Date of deposit of biological materials at Loi depository, September 11, 2007 (original deposit date)
September 5, 2008 (Date of transfer to deposit under the Budapest Treaty by original deposit)
Deposit number FERM BP-11012 attached to the depositary by the high depository
(4) Antibody No. 77205
The name and address of the depository that deposited the biological material AIST National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center 1-chome, East 1-chome, Tsukuba City, Ibaraki Prefecture, Japan 6 (zip code 305-8566)
Date of deposit of biological materials at Loi depository, September 11, 2007 (original deposit date)
September 5, 2008 (Date of transfer to deposit under the Budapest Treaty by original deposit)
Deposit number FERM BP-11013 attached by the depository in Hai for the deposit
(5) Antibody No. 77206
The name and address of the depository that deposited the biological material AIST National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center 1-chome, East 1-chome, Tsukuba City, Ibaraki Prefecture, Japan 6 (zip code 305-8566)
Date of deposit of biological materials at Loi depository, September 11, 2007 (original deposit date)
September 5, 2008 (Date of transfer to deposit under the Budapest Treaty by original deposit)
Deposit number FERM BP-11014 assigned by the depository in Thailand for deposit
(6) Antibody No. 77207
The name and address of the depository that deposited the biological material AIST National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center 1-chome, East 1-chome, Tsukuba City, Ibaraki Prefecture, Japan 6 (zip code 305-8566)
Date of deposit of biological materials at Loi depository, September 11, 2007 (original deposit date)
September 5, 2008 (Date of transfer to deposit under the Budapest Treaty by original deposit)
Deposit number FERM BP-11015 assigned by the depository in Thailand for deposit
(7) Antibody No. 77209
The name and address of the depository that deposited the biological material AIST National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center 1-chome, East 1-chome, Tsukuba City, Ibaraki Prefecture, Japan 6 (zip code 305-8566)
Date of deposit of biological materials at Loi depository, September 11, 2007 (original deposit date)
September 5, 2008 (Date of transfer to deposit under the Budapest Treaty by original deposit)
Deposit number FERM BP-11016 assigned by the depository in Hai for the deposit

Claims (16)

Using an antibody that reacts with a compound represented by the following formula (I) and does not cross-react with N-oxide and / or demethylated metabolite thereof:
An immunological measurement method for a compound represented by the following formula (I) in a sample.
  The immunoassay method according to claim 1, wherein the antibody is an antibody that reacts strongly with the S form of the compound represented by formula (I).   The immunological measurement method according to claim 1, wherein the antibody is an antibody that reacts strongly with the R form of the compound represented by formula (I).   The immunoassay method according to claim 1, wherein the antibody is an antibody that reacts strongly with a racemate of the compound represented by formula (I).   The antibody is selected from the group consisting of diclofenac sodium, nabumetone, flurbiprofen, ketoprofen, loxoprofen sodium, oxaprozin, naproxen, ibuprofen, carbocysteine, salicylamide, acetaminophen, anhydrous caffeine, methylenedisalicylic acid, promethazine and theophylline. The immunological measurement method according to claim 1, which is an antibody that does not cross-react with any one or more of the above.   The immunoassay method according to claim 1, wherein the antibody is an antibody that does not cross-react with a new quinolone antibacterial agent excluding the compound represented by formula (I) or has weak cross-reactivity. The immunological measurement method according to claim 1, wherein the reactivity of the antibody with the compound represented by formula (I) is an antibody that does not change due to the coexistence of a serum component, a plasma component, or a saliva component . The immunological measurement method according to any one of claims 1 to 7 , wherein the antibody is a monoclonal antibody. The antibody is immobilized on a solid phase, and the synthetic multivalent antigen and a compound represented by the formula (I) in a sample are competitively reacted with the antibody. 9. The immunological measurement method according to any one of 1 to 8 . The immunoassay according to any one of claims 1 to 9 , wherein the antibody is competitively reacted with the immobilized polyvalent antigen and the compound represented by the formula (I) in the sample. Method. The antibody is immobilized on a solid phase, and the antibody is competitively reacted with a solid-phased synthetic multivalent antigen and a compound represented by formula (I) in a sample, The immunological measurement method according to any one of claims 1 to 10 . The immunoassay method according to any one of claims 1 to 11 , wherein the solid phase is latex particles. The immunological measurement method according to any one of claims 1 to 12 , wherein the competitive reaction is measured by an aggregation inhibition method. The immunological measurement method according to any one of claims 1 to 13 , wherein the sample is blood, serum, plasma, urine, saliva, sputum, tears, otorrhea or prostate fluid derived from an organism. The immunoassay method according to claim 14 , wherein the sample is a sample of a patient administered with the compound represented by formula (I). A reagent for immunological measurement of a compound represented by formula (I) in a sample, characterized by comprising the following (a) and (b):
(A) an antibody which is used in the measurement method according to any one of claims 1 to 8 and is immobilized on a solid phase or not immobilized on a solid phase; (b) a synthetic multivalent antigen or solid phase Synthetic multivalent antigen